|
1
|
Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
|
J Clin Oncol
|
2004
|
4.67
|
|
2
|
Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia.
|
Diagn Microbiol Infect Dis
|
2010
|
2.41
|
|
3
|
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose.
|
J Antimicrob Chemother
|
2006
|
1.96
|
|
4
|
Safety and efficacy of intravenous tigecycline in subjects with secondary bacteremia: pooled results from 8 phase III clinical trials.
|
Clin Infect Dis
|
2010
|
1.92
|
|
5
|
A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer.
|
Clin Cancer Res
|
2006
|
1.75
|
|
6
|
Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.
|
Clin Cancer Res
|
2005
|
1.59
|
|
7
|
Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.
|
Cancer Res
|
2003
|
1.59
|
|
8
|
Integrated results of 2 phase 3 studies comparing tigecycline and levofloxacin in community-acquired pneumonia.
|
Diagn Microbiol Infect Dis
|
2008
|
1.40
|
|
9
|
Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin.
|
Diagn Microbiol Infect Dis
|
2008
|
1.33
|
|
10
|
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2010
|
1.07
|
|
11
|
A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
|
J Antimicrob Chemother
|
2008
|
1.06
|
|
12
|
Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.
|
Invest New Drugs
|
2009
|
0.92
|
|
13
|
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia.
|
Antimicrob Agents Chemother
|
2011
|
0.88
|
|
14
|
A sensitive human bone assay for quantitation of tigecycline using LC/MS/MS.
|
J Pharm Biomed Anal
|
2008
|
0.79
|